On 9 June, Alzheimer Europe hosted an online Company Round Table meeting, attended by representatives from Abbvie, Biogen, Eisai, Essity, GE Healthcare, Grifols, Janssen, Lilly, Lundbeck, Nutricia, Roche and TauRX. Also in attendance, were: 7 members of the AE staff, including Executive Director Jean Georges; 25 representatives of AE member organisations from 17 different countries; and 1 representative of the European Working Group of People with Dementia (EWGPWD).
Jean Georges updated sponsors and other delegates on Alzheimer Europe’s activities during the COVID-19 pandemic. Policy Officer Owen Miller shared some recent policy developments at the EU and national levels and Project Officer Cindy Birck gave an overview of recent developments with regards our Clinical Trials Watch database. Two company representatives then addressed delegates with presentations related to COVID-19: Lennert Steukers from Janssen discussed the impact of the pandemic on the neurodegeneration portfolio of the Innovative Medicines Initiative (IMI), and Martin Traber from Roche shared experiences of some of the implications for clinical trials. Finally, Gavin Terry highlighted the impact COVID-19 has had on the research programme of the Alzheimer’s Society (UK). We would like to thank our sponsors for participating in this meeting and we look forward to welcoming them to the next Company Round Table meeting, on 8 December 2020.
